LAVAL, QC and CAMBRIDGE, England, Sept. 15, 2023 /PRNewswire/ – Liminal BioSciences Inc. (NASDAQ: LMNL) (“Liminal BioSciences” or the “Company”), is pleased to announce that its shareholders have approved the previously-announced plan of arrangement under section 192 of the Canada…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.